Candel Therapeutics (CADL) Debt to Equity (2020 - 2025)

Candel Therapeutics has disclosed Debt to Equity across 6 years of filings, most recently posting $0.02 for Q4 2025.

• Debt to Equity for Q4 2025 came in at $0.02, down 88.04% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.02 (down 88.04% YoY), and the FY2025 annual result was $0.02, down 88.04% from the prior year.
• Debt to Equity came in at $0.02 for Q4 2025 at Candel Therapeutics, down from $0.05 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $3.17 in Q1 2024 to a low of -$1.06 in Q2 2024.
• The 5-year median for Debt to Equity is $0.13 (2025), against an average of $0.37.
• Across the five-year window, Debt to Equity jumped 6479.07% in 2023 and tumbled 260.98% in 2024, its largest moves.
• Candel Therapeutics' Debt to Equity stood at $0.01 in 2021, then jumped by 4749.19% to $0.42 in 2022, then jumped by 280.36% to $1.61 in 2023, then slumped by 89.92% to $0.16 in 2024, then tumbled by 88.04% to $0.02 in 2025.
• The last three Debt to Equity figures came in at $0.02 (Q4 2025), $0.05 (Q3 2025), and $0.07 (Q2 2025), per Business Quant data.